Access the full text.
Sign up today, get DeepDyve free for 14 days.
R. Steckel, A. Kagan (1980)
Diagnostic persistence in working up metastatic cancer with an unknown primary site.Radiology, 134 2
Satoh (2001)
1305Oncology Reports, 8
H. Satoh, H. Ishikawa, Y. Yamashita, K. Kurishima, M. Ohtsuka, K. Sekizawa (2001)
Peritoneal carcinomatosis in lung cancer patients.Oncology reports, 8 6
Kavanagh Kavanagh, Ouellet Ouellet (2006)
Clinical practice guideline on peritoneal carcinomatosis treatment using surgical cytoreduction and hyperthermic intraoperative intraperitoneal chemotherapyBulletins in Cancer, 93
B. Moran, A. Mukherjee, R. Sexton (2006)
Operability and early outcome in 100 consecutive laparotomies for peritoneal malignancyBritish Journal of Surgery, 93
N. Pavlidis, E. Briasoulis, J. Hainsworth, F. Greco (2003)
Diagnostic and therapeutic management of cancer of an unknown primary.European journal of cancer, 39 14
J. Abbruzzese, M. Abbruzzese, K. Hess, M. Raber, R. Lenzi, P. Frost (1994)
Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 12 6
J. Nystrom, J. Weiner, J. Heffelfinger-Juttner, L. Irwin, J. Bateman, R. Wolf (1977)
Metastatic and histologic presentations in unknown primary cancer.Seminars in oncology, 4 1
N. Pavlidis, K. Fizazi (2005)
Cancer of unknown primary (CUP).Critical reviews in oncology/hematology, 54 3
Seeber Seeber, Strumberg Strumberg (2006)
Metastases with CUP syndromeDer Urologe A, 45
Frost (1989)
139Cancer Bulletin, 41
D. Ransom, Shreyaskumar Patel, G. Keeney, G. Malkasian, J. Edmonson (1990)
Papillary serous carcinoma of the peritoneum. A review of 33 cases treated with platin‐based chemotherapyCancer, 66
Heinemann (2002)
9Seminars of Oncology, 29
Bar-Eli (1993)
1619Anti-Cancer Research, 13
R. Harmon, P. Sugarbaker (2005)
Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancerInternational seminars in surgical oncology : ISSO, 2
O. Glehen, E. Cotte, V. Schreiber, A. Sayag-Beaujard, J. Vignal, F. Gilly (2004)
Intraperitoneal chemohyperthermia and attempted cytoreductive surgery in patients with peritoneal carcinomatosis of colorectal originBritish Journal of Surgery, 91
V. Heinemann (2002)
Gemcitabine in the treatment of advanced pancreatic cancer: a comparative analysis of randomized trials.Seminars in oncology, 29 6 Suppl 20
Sugarbaker (1996)
82
Frost Frost, Raber Raber, Abbruzzese Abbruzzese (1989)
Unknown primary tumors as a unique clinical and biological entity: a hypothesisCancer Bulletin, 41
Sugarbaker Sugarbaker (2003)
Peritonectomy proceduresSurgical Oncology, 12
Babak Sadeghi, C. Arvieux, O. Glehen, A. Beaujard, M. Rivoire, J. Baulieux, E. Fontaumard, A. Brachet, J. Caillot, J. Faure, J. Porcheron, J. Peix, Y. François, J. Vignal, F. Gilly (2000)
Peritoneal carcinomatosis from non‐gynecologic malignanciesCancer, 88
M. Kavanagh, Jean Ouellet (2006)
Guide de pratique clinique sur le traitement de la carcinomatose péritonéale par cytoréduction chirurgicale et chimiothérapie hyperthermique intrapéritonéale peropératoireBulletin Du Cancer, 93
J. Hainsworth, W. Lennington, F. Greco (2000)
Overexpression of Her-2 in patients with poorly differentiated carcinoma or poorly differentiated adenocarcinoma of unknown primary site.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 18 3
Kavanagh (2006)
867Bulletins in Cancer, 93
V. Karavasilis, V. Malamou-Mitsi, E. Briasoulis, E. Tsanou, E. Kitsou, H. Kalofonos, G. Fountzilas, T. Fotsis, N. Pavlidis (2005)
Angiogenesis in cancer of unknown primary: clinicopathological study of CD34, VEGF and TSP-1BMC Cancer, 5
Y. Iitsuka, S. Kaneshima, O. Tanida, T. Takeuchi, S. Koga (1979)
Intraperitoneal free cancer cells and their viability in gastric cancerCancer, 44
A. Wouw, M. Janssen-Heijnen, J. Coebergh, H. Hillen (2002)
Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984-1992.European journal of cancer, 38 3
M. Bar‐eli, James Abbruzzese, D. Lee-Jackson, Philip Frost (1993)
p53 gene mutation spectrum in human unknown primary tumors.Anticancer research, 13 5A
D. Alberts, P. Liu, E. Hannigan, R. O'Toole, S. Williams, S. Williams, J. Young, E. Franklin, D. Clarke‐Pearson, V. Malviya, B. Dubeshter, B. Dubeshter, M. Adelson, W. Hoskins (1996)
Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.The New England journal of medicine, 335 26
Nystrom (1977)
53Seminars in Oncology, 4
S. Seeber, D. Strumberg (2006)
Metastasen mit unbekanntem Primärtumor (CUP)Der Urologe, 45
A. Stephens, Robert Alderman, D. Chang, G. Edwards, J. Esquivel, G. Sebbag, M. Steves, P. Sugarbaker (1999)
Morbidity and Mortality Analysis of 200 Treatments With Cytoreductive Surgery and Hyperthermic Intraoperative Intraperitoneal Chemotherapy Using the Coliseum TechniqueAnnals of Surgical Oncology, 6
J. Abbruzzese, M. Abbruzzese, R. Lenzi, K. Hess, M. Raber (1995)
Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 13 8
L. Veer, B. Weigelt (2003)
Road map to metastasisNature Medicine, 9
G. Sebbag, B. Shmookler, D. Chang, P. Sugarbaker (2001)
Peritoneal Carcinomatosis from an Unknown Primary Site. Management of 15 PatientsTumori Journal, 87
S. Culine, A. Kramar, M. Saghatchian, R. Bugat, T. Lesimple, A. Lortholary, Y. Merrouche, A. Laplanche, K. Fizazi (2002)
Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 24
Jonathan Sporn, Bernard Greenberg (1990)
Empiric chemotherapy in patients with carcinoma of unknown primary site.The American journal of medicine, 88 1
Chu Chu, Lang Lang, Thompson Thompson, Osteen Osteen, Westbrook Westbrook (1983)
Peritoneal carcinomatosis in non gynaecological malignancyCancer, 63
G. Pentheroudakis, E. Briasoulis, V. Karavassilis, G. Fountzilas, Nikolaos Xeros, G. Samelis, E. Samantas, N. Pavlidis (2005)
Chemotherapy for patients with two favourable subsets of unknown primary carcinoma: Active, but how effective?Acta Oncologica, 44
D. Chu, N. Lang, C. Thompson, P. Osteen, K. Westbrook (1989)
Peritioneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factorsCancer, 63
R. Pasterz, N. Savaraj, M. Burgess (1986)
Prognostic factors in metastatic carcinoma of unknown primary.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 4 11
Gilly (1994)
124Hepatogastroenterology, 41
Sugarbaker (2003)
703Surgical Oncology, 12
Sadeghi Sadeghi, Arvieux Arvieux, Glehen Glehen, Beaujard Beaujard, Rivoire Rivoire, Baulieux Baulieux, Fontaumard Fontaumard, Brachet Brachet, Caillot Caillot, Faure Faure, Porcheron Porcheron, Peix Peix, Francois Francois, Vignal Vignal, Gilly Gilly (2000)
Peritoneal carcinomatosis from non‐gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective studyCancer, 88
F. Gilly, P. Carry, Sayag Ac, A. Brachet, G. Panteix, B. Salle, J. Bienvenu, G. Burgard, B. Guibert, V. Banssillon (1994)
Regional chemotherapy (with mitomycin C) and intra-operative hyperthermia for digestive cancers with peritoneal carcinomatosis.Hepato-gastroenterology, 41 2
Karl Chen, M. Flam (1986)
Peritoneal papillary serous carcinoma with long‐term survivalCancer, 58
Peritoneal seeding of cancer cells leading to peritoneal carcinomatosis (PC) is an ominous finding that has primarily been described in women with underlying ovarian malignancy. It is also a common development in patients with gastrointestinal malignancy and may sometimes occur in the absence of a known, identified primary malignancy. Peritoneal carcinomatosis resulting from a cancer of unknown primary (CUP) is a rare and ill‐defined entity, and as a result, there is no clear guidance on the most effective management strategy for this group of patients. The indiscriminate use of numerous investigations in an attempt to identify a primary malignant focus is discouraged. A subjective approach to the patient, with the aim of identifying patients who would benefit from therapeutic management and those who should be managed with palliative intent, should be employed. Aggressive therapeutic measures such as cytoreduction, peritonectomy and hyperthermic intraoperative intraperitoneal chemotherapy may offer some long‐term survival, but selection of appropriate patients is essential. Large randomized studies are needed in patients with PC secondary to CUP to determine the efficacy of such treatment options. Studies into the pathogenesis and molecular pathways of this condition are required to improve understanding and guide development of novel therapeutic strategies.
European Journal of Cancer Care – Wiley
Published: Jan 1, 2009
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.